Superworth

Neogen price to free cash flow NEOG

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
53.5×
10-year median
65.7×
Against its 10-year history
15th
percentile: 0 is its lowest day, 100 its highest
10-year range
36.6× to 366×
Peer median
27.2×

Neogen's price to free cash flow is 53.5× as of Oct 23, 2026.

That is below its ten-year median of 65.7×, lower than on 85% of days in the last ten years.

Over that time it ranged from 36.6× in Sep 2022 to 366× in Jul 2026.

The median for 9 diagnostics and research stocks of a similar size is 27.2×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far53.5×51.8×366×
2025n/m a value too high to mean anything
2024184×184×233×
2023n/m a value too high to mean anything
202236.6×36.6×80.2×
202191.0×60.2×91.0×
202059.8×52.1×75.2×
201967.3×51.2×83.5×
201851.0×51.0×104×
201754.7×40.8×62.2×
201659.9×43.1×81.3×
201552.8×39.8×62.9×
201493.2×65.0×122×
201367.1×40.0×74.6×
201238.8×38.8×72.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest Neogen's size, closest first, today.

CompanyPrice to free cash flow
NEOGNeogen53.5×
CDNACareDxn/m
VCYTVeracyte23.2×
BLLNBillionToOne153×
LNTHLantheus16.8×
CAICaris Life Sciences73.0×
BIOBio-Rad Laboratories28.0×
NRCNRC Health22.4×
RVTYRevvity31.7×
MEDPMedpace26.4×
Peer median27.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Neogen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.